Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Down 57.0% in April

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 115,600 shares, a decline of 57.0% from the March 31st total of 268,900 shares. Based on an average daily volume of 111,900 shares, the short-interest ratio is presently 1.0 days. Approximately 2.6% of the company’s shares are sold short.

Salarius Pharmaceuticals Stock Performance

Shares of SLRX remained flat at $0.50 during mid-day trading on Friday. The stock had a trading volume of 4,071 shares, compared to its average volume of 39,317. The business has a 50-day simple moving average of $0.56 and a 200-day simple moving average of $0.62. Salarius Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $2.31.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.79. Research analysts forecast that Salarius Pharmaceuticals will post -26.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Salarius Pharmaceuticals

An institutional investor recently raised its position in Salarius Pharmaceuticals stock. Armistice Capital LLC increased its position in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) by 105.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 225,000 shares of the company’s stock after purchasing an additional 115,364 shares during the period. Armistice Capital LLC owned 5.71% of Salarius Pharmaceuticals worth $148,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.88% of the company’s stock.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.